- Trial Phase
- Phase 2 complete (positive); Phase 3 planned/initiating 2H 2026
- Time to Market
- Phase 3 initiation guided to 2H 2026 with a company-flagged potential 2029 commercial launch in atopic dermatitis — roughly 3 years from now, assuming Phase 3 success and a standard filing/PDUFA path.
- Why 4/10
- No hard, dated binary for this drug within ~12 months: the Phase 2 readout (the defining catalyst) already passed in May 2026, Phase 3 initiation and the Dupixent head-to-head interim are only guided to "2H 2026" windows, and the next dated event is the Q3 2026 AbbVie deal close — an M&A completion, not a drug decision — with a potential 2029 launch still ~3 years out; APGE's stock is already pinned near the $135.11 cash offer, and for ABBV the asset is a small part of a much larger pipeline, so impact is capped at 4.
For APGE holders, the drug's upside is essentially monetized — the stock trades ~0.7% below the $135.11 all-cash offer, so the remaining question is simply whether the AbbVie deal closes in Q3 2026 (mean analyst target $130.53 vs. price ~$134 reflects the capped upside). For AbbVie investors, zumilokibart is a 2030s thesis: watch Phase 3 initiation in atopic dermatitis (guided 2H 2026), interim data from the head-to-head versus Dupixent (2H 2026), and the ~$0.14 FY2026 EPS dilution the deal carries — the Phase 3 readouts that could validate the ~$10.9B price tag are years away.
Price Chart
Executive Summary
Zumilokibart (APG777) is Apogee Therapeutics' lead asset — a half-life-extended anti-IL-13 antibody in development for atopic dermatitis, asthma, and eosinophilic esophagitis — and the reason AbbVie agreed on June 22, 2026 to buy Apogee for $135.11 per share in cash (~$10.9 billion), AbbVie's largest deal in more than half a decade. Phase 2 APEX data were positive (Part B: 65.9% EASI-75 vs. 23.4% placebo, p<0.001; Part A: durable 52-week maintenance on every-3/6-month dosing), supporting Phase 3 initiation in 2H 2026 and a potential 2029 launch, with up to $1.3B in Blackstone Life Sciences non-dilutive financing already secured. The developer stock (APGE) now trades ~0.7% below the cash offer, so the remaining near-term binary is the deal close (expected Q3 2026), not a drug readout; for AbbVie, zumilokibart is a 2030s "mega-blockbuster" bet that carries ~$0.14 of 2026 EPS dilution.
How It Works
An engineered antibody (biologic) that binds and blocks IL-13, a signaling protein that drives "type 2" inflammation — the allergic, itchy skin inflammation behind eczema (atopic dermatitis), asthma, and eosinophilic esophagitis. Zumilokibart is engineered with a longer half-life so, after a loading phase, patients may only need a subcutaneous injection every 3–6 months instead of the roughly monthly dosing typical of standard eczema biologics like Sanofi/Regeneron's Dupixent.
Trial Status
Phase 2 APEX trial in moderate-to-severe atopic dermatitis: Part A 52-week data (Mar 23, 2026) showed durable maintenance and deepening responses with every-3- and every-6-month dosing (75%/85% maintained EASI-75; 86%/78% maintained vIGA 0/1); Part B 16-week data (May 27, 2026) met all primary and secondary endpoints, with mid-dose EASI-75 of 65.9% vs. 23.4% placebo (p<0.001) and a favorable safety profile. Phase 3 initiation in AD is planned for 2H 2026; positive Phase 1b asthma data earlier in 2026 supports expansion, with eosinophilic esophagitis (EoE) trials planned and a head-to-head trial vs. Dupixent with interim data expected 2H 2026.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026: expected close of AbbVie's $10.9B acquisition of Apogee at $135.11/share cash
- 2H 2026: Phase 3 trial initiation in moderate-to-severe atopic dermatitis
- 2H 2026: interim data from the head-to-head trial versus Dupixent
- Later 2026: additional trial details for asthma and eosinophilic esophagitis (EoE)
- Longer term: Phase 3 readouts and potential 2029 commercial launch (for AbbVie shareholders)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report